Research never stops

Neurology

The central nervous system (“CNS”) represents the largest part of the nervous system, including the brain and the spinal cord. Together with the peripheral nervous system, it has a fundamental role in the control of behaviour.

Neurodegenerative disease is an umbrella term for a range of conditions which primarily affect the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally don’t reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Examples of neurodegenerative diseases include Parkinson’s, Alzheimer’s and Huntington’s disease.

Alzheimer’s disease late-stage opportunity drives Evotec’s CNS pipeline:

Molecule(s)

Indication
(mechanism)

Partner Status Next milestone Commercials
EVT3021) Alzheimer’s disease (MAO-B) Roche

Phase IIb

Completion of Phase II, Phase III start $ 10 m upfront, up to $ 820 m milestones, significant royalties
EVT201 Insomnia JingXin Phase II Start clinical trials Milestones, royalties
EVT100 series1) CNS diseases
(TRD)
Janssen Pharmaceuticals Phase II/
Pre-clinical
Confirmation of pre-clinical study/ Phase II start $ 2 m upfront, up to $ 173 m milestones, significant royalties
TargetAD

Alzheimer’s disease

(Novel MoA)

Johnson & Johnson Innovation Discovery ND Up to $ 10 m research payments, approx. $ 125-145 m milestones, royalties
TargetASIC Multiple sclerosis BMBF/ undisclosed Pharma Discovery Lead status Co-funded
CureMN ALS

Harvard

University

ND Pharma partnership TBD

TargetaSN Parkinsons's disease MJFF ND ND ND

1) Evotec has regained the licence rights and is currently assessing potential business opportunities

Neurology

Celgene/ Neurodegenerative diseases

- read more

Roche/EVT302

- read more

JingXin/EVT201

- read more

Janssen/EVT100 series

- read more

JnJ Innovation/TargetAD

- read more

BMBF/TargetASIC

- read more

Harvard/CureMN

- read more